Novartis has five business segments and is supported by our global research organization, the Novartis Institutes for BioMedical Research (NIBR). These segments are strategically aligned to bring innovative, high-quality and affordable medicines and therapies to patients around the world.
Making full use of its cross-divisional cooperation potential, Novartis continually looks for opportunities to leverage the strength of its global and diverse businesses to meet patient needs and extend its differentiated leadership position.
We continuously evolve our businesses to create a patient-centered portfolio consisting of a wide range of products and treatments to address unmet medical needs.
- In January 2014, Novartis completed the divestment of its blood transfusion diagnostics unit to Grifols for USD 1.7 billion.